Wall Street Zen Downgrades Ocugen Stock to Sell

Analysts cite concerns over the biotech company's future prospects.

Apr. 4, 2026 at 5:37am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of heavy, industrial-looking financial mechanisms and machinery, conveying a sense of the intricate workings and power of the financial system as a metaphor for the challenges facing biotech companies.An extreme close-up of the complex machinery underlying the financial markets, reflecting the uncertainty and challenges facing biotech companies like Ocugen.Malvern Today

Wall Street Zen, a prominent research firm, has downgraded shares of Ocugen (NASDAQ:OCGN) from a 'hold' rating to a 'sell' rating in a new report released on Saturday. The downgrade comes as several other analysts have also issued mixed ratings on the biotech company's stock in recent months.

Why it matters

Ocugen is a clinical-stage biotech company focused on developing gene therapies for rare inherited retinal diseases and vaccines for infectious diseases. The Wall Street Zen downgrade reflects growing uncertainty around the company's future prospects and ability to deliver on its pipeline of treatments.

The details

In its report, Wall Street Zen cited concerns over Ocugen's financial performance and the challenges it faces in advancing its drug candidates through clinical trials and regulatory approval. The firm's analysts believe the company's stock is overvalued at current levels and that investors should consider selling their positions.

  • Wall Street Zen released its downgrade report on Saturday, April 4, 2026.

The players

Wall Street Zen

A prominent research firm that provides analysis and ratings on publicly traded companies.

Ocugen

A clinical-stage biopharmaceutical company focused on developing gene therapies for rare inherited retinal diseases and vaccines for infectious diseases.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Ocugen's upcoming financial results and pipeline updates to gauge the company's progress and determine if the Wall Street Zen downgrade is warranted.

The takeaway

The Wall Street Zen downgrade highlights the ongoing challenges and uncertainties facing Ocugen as it works to advance its drug candidates and gain traction in the highly competitive biotech industry. Investors will need to carefully evaluate the company's long-term prospects before making investment decisions.